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1. Introduction
Since the introduction of endoscopic ultrasound (EUS) in the 1980s, EUS-guided fine needle
aspiration (EUS-FNA) has become increasingly popular for the diagnosis and staging of gas‐
trointestinal diseases, and peri-gastrointestinal lesions, especially in the areas of pancreatic
or peri-pancreatic mass-like lesions. The application of FNA has dramatically expanded the
clinical utility of EUS[1-10].
The aims of this chapter are to review:
1. The advantage of EUS-FNA in cytopathology diagnosis over other diagnostic modalities.
2. The impact of on-site cytological interpretation on the diagnostic yield of EUS-FNA.
3. The difference of application of ancillary techniques in cytological as compared to sur‐
gical specimens. What are the drawbacks but also the advantages of applying immuno‐
cytochemistry (ICC) in EUS-FNA obtained specimens.
4. Why EUS-FNA material can be an ideal source of material for molecular studies.
5. In summary, the full value of EUS-FNA can only be achieved with an integrated approach.
We will illustrate this approach by one of our interesting EUS-FNA case studies.
2. Aim 1: The advantage of EUS-FNA in cytopathology diagnosis over
other diagnostic modalities
In the absence of EUS-FNA, there are many alternatives for obtaining biopsy specimens of
mass lesions in the chest and abdomen [11]. This is done most frequently by transcutaneous
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ultrasound (TUS), or CT-guided biopsy. Pathology specimens of obstructing lung masses
and/or large paratracheal lymph nodes often are obtained at bronchoscopy with forceps or
by transbronchial needle aspiration. Pathology specimens of pancreatic masses, especially
those causing obstructive jaundice are still commonly obtained at the time of diagnostic or
therapeutic ERCP (endoscopic retrograde cholangiopancreatography) with brushing, needle
aspiration, or intraductal biopsy forceps. When lesions cannot be accessed by the above
techniques, more invasive methods, such as mediastinoscopy or operative biopsy (laparo‐
scopic or open) are used. The primary limitations of TUS and CT-guided aspiration include
difficulty in accurately targeting small lesions and finding a safe-skin-to-lesion route, espe‐
cially for deep-seated retroperitoneal, mediastinal or perirectal lesions. The diagnostic yield
of pancreatic malignancies with ERCP biopsy is particularly problematic, with reported sen‐
sitivities ranging from 20% to 80%, and most series having yields of a definitive malignant
diagnosis of only around 50%. The complication rate for ERCP cytologic brushing is report‐
edly as high as 11% for the biliary tree and 21% for pancreatic strictures [12-14].
Commercial radial echoendoscopes were introduced by the Olympus Corporation in 1987.
Although EUS-FNA was performed successfully with radial echoendoscopes, it was not un‐
til 1991, when the linear-array echoendoscopes by Pentax Precision Instruments were intro‐
duced, that EUS-FNA has been extensively utilized for a variety of lesions. Fundamentally,
EUS-FNA involves passing an 18- to 25-gauge aspiration needle through the biopsy port of
an echoendoscope under real-time guidance into a EUS visualized mass lesion, lymph node,
lesion within another organ, or fluid collection.
Although EUS is considered superior to MRI or CT with cross-sectional imaging for tumor
detection smaller than 2 to 3 cm [15, 16], it is the ability to target and place a needle into
suspicious lesions at the closest proximity between the tip of the echoendoscope and the tar‐
geted lesion that has made EUS-FNA indispensable in the pre-operative diagnosis, especial‐
ly in situations where neoadjuvant therapies or non-surgical management might be the
clinical choice. Determining the role of EUS-FNA when alternative diagnostic modalities are
available is difficult to assess in clinical trials; however, decision analysis models have been
used to study the impact of EUS-FNA in lesions of many sites, including non-small-cell lung
cancer with mediastinaladenopathy [17, 18], esophageal cancer and pancreatic cancer
[19-21]. Commonly employed diagnostic modalities including CT-guided or US-guided
FNA, ERCP with brushing, laparoscopic surgical biopsy and EUS-FNA have been analyzed
for their costs, failure rate, testing characteristics and complication rate. In each of these
analyses, EUS-FNA is the most cost-effective approach as the primary diagnostic modality
and the preferred secondary alternative method after a failed initial diagnostic method as
the least costly follow-up method.
The overall complication rate of EUS-FNA appears to be about 1-2% [22, 23], comparable to
that reported with CT or US-guided FNA or biopsy. However, another significant factor fa‐
voring EUS-FNA over transcutaneous biopsy is avoiding the possible risk of needle-tract
seeding[24]. During EUS-FNA the aspiration needle travels from the gut lumen to the lesion,
a pathway that usually does not involve significant crossing of peritoneal or pleural surfa‐
ces. In addition, endosonographers may have multiple options for the most accessible ap‐
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proach to a lesion, such as through esophageal, gastric or duodenal path. In the case of
pancreatic neoplasms, because of EUS-FNA imaging advantages, high diagnostic yields and
concern over needle-tract seeding with transcutaneous aspiration, the 6th edition of the
handbook on cancer staging by the American Joint Committee on Cancer has recommended
EUS-FNA as the preferred sampling technique in pancreatic masses if available[25].
Lastly, EUS-FNA has also opened the era of interventional endoscopic ultrasound (IEUS). In
the same way as FNA, the close proximity between the needle tip and the targeted organ
allows therapeutic procedures, such as injection therapies, to be performed safely and effec‐
tively. This includes EUS-guided celiac plexus neurolysis and block for pain relief, drainage
of pancreatic pseudocysts and pelvic fluid collections, and implantation of fiducial markers
and radioactive seeds into malignant tumors. Other emerging EUS-guided experimental
techniques include antitumor injection, ablation of tumors, and vascular access. IEUS is a
very promising technique with many potential applications [26-28].
On a different note, performance quality in endoscopy is becoming an important issue for
patient care. Currently there is no universally accepted method for performance quality in‐
dicators in EUS, mostly because cancer staging accuracy cannot be verified without surgical
resection. In addition, FNA yields of many sites (such as mediastinal lymph nodes) vary
greatly based on pretest probabilities. Because most pancreatic masses that undergo EUS-
FNA have a very high pretest probability of being malignant and most endosonographers
agree that pancreatic neoplasms are among the most difficult lesions on which to perform
EUS-FNA, the diagnostic yield of EUS-FNA of solid pancreatic masses has become a bench‐
mark for EUS-FNA quality. Much of the data for performance quality has come from series
on pancreatic EUS-FNA, which is also the approach of most of our studies discussed in this
chapter. In a multicenter retrospective study of 1075 patients who underwent EUS-guided
FNA of solid pancreatic masses, the overall diagnostic rate of malignancy was 71%, the me‐
dian rate per center was 78% and the median rate per endoscopist was 75% [29], remarkably
higher than any other aforementioned diagnostic modalities.
The ideal benchmark for pancreatic EUS-FNA performance, however, would be the actual
sensitivity and specificity of diagnosing malignancy and require the criterion standard of ei‐
ther surgical pathology or long-term follow-up, which is the focus of our studies in the next
section.
3. Aim 2: Efficacy and utility of immediate cytologic interpretation on the
diagnostic yield of EUS-FNA of solid and cystic pancreatic and peri-
pancreatic lesions
Intra-procedural on-site immediate interpretation by a cytopathologist is not performed in
some clinical settings. Having a cytopathologist on site is time-consuming and diverts the
pathologist from other duties, and the cytopathologist time is not compensated at the same
rate as routine surgical pathology [30, 31]. In the setting of service time pressure, there is a
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need for evidence based decisions regarding how to allocate pathologists. The clinical im‐
pact of immediate interpretation provided by cytopathologists during the EUS-FNA proce‐
dure and the statistical significance of this cytologic service has been well-
documented[32-43], although with variable conclusions. Many of the previous studies have
included a wide range of disease entities sampled by EUS-FNA procedure. In addition, by
including cystic lesions, previous analysis has been complicated by the high likelihood of
acellular or pauci-cellular specimens obtained from the cystic lesions, which could be inter‐
preted as inadequate on cytology. Thus, the clarity of outcome measurements from previous
studies has been hindered by the complexity of the diseases included, and by inclusion of
cystic lesions with an unduly high “inadequacy” rate. In addition, many previous studies
have used clinical survival years as a surrogate for final assessment of diagnostic accuracy.
Our goal in the hereby presented study is to use EUS-FNA of solid pancreatic masses as the
benchmark procedure to compare diagnostic yield and accuracy in a strictly defined clinical
setting of EUS-FNA performed in the presence or absence of on-site immediate cytologic in‐
terpretation. Histologic examination is used as the gold standard for comparison.
To avoid the confounding sampling issues of cystic lesions, this study was focused on the
diagnostic yield of EUS-FNA in non-cystic pancreatic mass-like lesions. A computer inven‐
tory search located 215 cases during the years 1999-2007 at University of Washington Medi‐
cal Center and Harborview Medical Center, both in Seattle, WA, USA. These included 100
cases where immediate cytologic interpretation was available and 115 cases without imme‐
diate interpretation. Surgical pathology and clinical follow-up information were evaluated
whenever possible. Comparison between the cytologic diagnoses with or without on-site
immediate cytologic interpretation was facilitated by well-documented cytology reports.
“Positive” specimens were defined as suspicious or malignant cytology. “Inadequate” speci‐
mens were defined as “rare atypical cells, non-diagnostic”; “essentially acellular specimen”,
or “gastrointestinal tract carry-over material”. “Negative” specimens were defined as “ade‐
quate cellularity with benign or reactive features”.
As shown in Table 1, the rate of inadequate specimens was significantly lower for cases with
immediate cytologic interpretation (1% versus 21%; p <0. 0001). Although not statistically
significant, there was a trend toward the need for fewer repeat procedures with the availa‐
bility of immediate evaluation (rate 5% versus 10%; p <0. 3).
N = Positive
On Cytology
N = Negative
On Cytology
Inadequate Case
N (%)
Repeat EUS-FNA
Procedure N (%)
Immediate Interpretation
(N = 100)
60 39 1 (1%) 5 (5%)
No immediate Interpretation
(N = 115)
58 33 24 (21%) 11 (10%)
P Value < 0. 0001 < 0. 3
Table 1. EUS-FNA of non-cystic pancreatic mass-like lesions with or without immediate interpretation for all cases
(N=215)
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Of the 215 cases, surgical pathology follow-up was available for 55 cases. As would be ex‐
pected, the majority of pancreatic mass lesions with surgical pathology comprised chronic
pancreatitis (n=14), pancreatic ductal adenocarcinoma (n=29), and pancreatic endocrine neo‐
plasms (n=7) (Table 2).
Case Type Case Number (N)
Chronic pancreatitis 14
Pancreatic ductal adenocarcinoma 29
Pancreatic endocrine neoplasm 7
Solid pseudopapillary neoplasm of pancreas 2
Lymphoma 2
Fibromatosis 1
Table 2. Cases with histologic diagnoses (total N=55)
With histologic follow-up, we identified one false positive case, both at immediate inter‐
pretation  and  at  final  cytologic  review,  for  which  no  neoplasm  was  identified  at  the
open surgery or at repeat EUS-FNA procedure; this may have been a reactive mass that
resolved after  resolution of  inflammation (with 12 months follow up).  Cases with nega‐
tive cytology results usually do not progress to surgical intervention, and surgical resec‐
tion  is  also  not  performed in  cases  with  unresectable  malignancy.  Due  to  the  expected
small  number  of  cytologically  negative  cases  with  histologic  follow-up,  the  single  false
positive case would have weighed un-proportionally in the calculation of specificity and
positive  predictive  value.  False  negative  cases  represented well-differentiated  pancreatic
adenocarcinomas  and  cases  of  unrepresentative  sampling,  including  one  case  of  fibro‐
matosis  of  pancreas.  The number of  cases with diagnostic  discrepancy between cytolog‐
ic  and histologic  diagnoses,  and the corresponding statistical  values,  are summarized in
Table  3  and  Table  4.  When  comparing  cases  with  on-site  cytopathology  immediate  in‐
terpretation  to  those  without,  there  was  a  trend toward greater  sensitivity  (83% versus
65%,  p=0.19)  with similar  specificity  (86% versus 100%,  p=0.29).  There  was also a  trend
toward lower  cytologic-histologic  discordance  rate  in  cases  with  availability  of  immedi‐
ate  interpretation  by  cytopathologists  (16% versus  27%,  p=0.34).  Positive  predictive  val‐
ue  was  comparable  for  cases  where  cytopathologists  were  present  on-site  compared
with cases  where no cytopathologists  were present  (94% versus 100%,  p=0.  32),  but  the
availability  of  immediate  interpretation  resulted  in  a  higher  negative  predictive  value
(67% versus 47%, p=0.34).
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N=Positive
cytology,
neoplastic
histology (TP)
N= Positive
cytology, benign
histology
(FP)
N=Benign
cytology,
benign
histology (TN)
N=Benign
cytology,
neoplastic
histology (FN)
N= Total histologic
follow-up available
(TP+FP+TN+FN)
On-Site
Interpretation
15 1 6 3 25
No On-Site
Interpretation
15 0 7 8 30
TP:True positive cytologic diagnosis
FP:False positive cytologic diagnosis
TN:True negative cytologic diagnosis
FN:False negative cytologic diagnosis
Table 3. Discrepancy between cytologic and histologic diagnoses (N=55)
Histologic
follow-up
available
Discordance rate Sensitivity Specificity PPV NPV
On-Site
Interpretation
25 16% 83% 86% 94% 67%
No On-Site
Interpretation
30 27% 65% 100% 100% 47%
Histological follow-up available: T=TP+FP+TN+FN
Discordance rate:FP+FN/T
Sensitivity:TP/TP+FN
Specificity:TN/TN+FP
Positive predictive value on cytology (PPV):TP/TP+FP
Negative predictive value on cytology (NPV):TN/TN+FN
Table 4. Performance characteristics according to the availability of on-site cytopathology (N=55 cases)
In this study, the drop of the inadequacy rate from 21% without on-site immediate interpre‐
tation to 1% with on-site immediate interpretation is highly statistically significant (p value
< 0.0001). The repeat procedure rate dropped correspondingly from 10% to 5%. It has been
shown that EUS-FNA would lose its advantage over the other diagnostic options if its fail‐
ure rate were over 20% [44]. The EUS-FNA procedure in various body sites (thyroid, breast,
lung, etc. ) generally has a comparable reported failure rate when performed without imme‐
diate interpretation, with an average failure rate of 20% and a maximum of reported failure
rate of 32% [32, 33, 45-47]. In our current study, without immediate interpretation, our inad‐
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equacy rate was 21%, a rate at which the procedure may not be cost effective over other di‐
agnostic options. On-site immediate cytology interpretation of EUS-FNA of solid pancreatic
lesions thus results in cost savings, reduced intervals between diagnosis and therapeutic in‐
tervention, and enhanced patient care.
An important task at the EUS-FNA procedure is representative sampling of the lesion. With
on-site immediate microscopic evaluation of part of the sample, an experienced cytologist
should be able to assess the cellularity of the sampling and to differentiate gastrointestinal
tract carryover material from moderately to poorly differentiated malignant cells. The pres‐
ence of dense numbers of inflammatory cells, necrotic debris, and fibrous stromal elements
provides good evidence that the endosonographer is actually sampling the targeted lesion.
In our experience, on-site communication with immediate feedback is invaluable in guiding
the next needle pass. Another indispensable value is that immediate evaluation gives the
pathologists the best opportunity to triage the sampled material for its optimal use, includ‐
ing sending fresh specimen for flow cytometry analysis for possible lymphoproliferative dis‐
ease, sending cyst contents for microbiology tests, or chemical analysis for tumor markers,
such as amylase, CEA, CA19-9, etc. All those commonly available laboratory tests cannot be
performed once the specimen is fixed.
What is the impact of EUS-FNA on-site evaluation in situations of non-solid pancreatic le‐
sions [48-52]? In our daily practice of cytology, EUS-FNA specimens comprise almost half the
volume of our on-site immediate assessment service. There are occasions when the aspirated
material has presented with an unusual or unexpected, and yet remarkable gross appearance.
On-site availability gives us the advantage of observing the gross appearance of freshly aspi‐
rated material. With increased experience, we feel these grossly “unusual” aspirates can ac‐
tually  help  to  raise  our  suspicion towards  a  relatively  specific  diagnosis  and triage  the
material for certain helpful laboratory tests. In our 2008 publication, we conducted 10-year in‐
stitutional case review and summarized three different patterns of gross appearance of aspi‐
rated material from non-neoplastic pancreatic and peri-pancreatic cystic lesions [53].
3.1. Pattern 1: Grossly yellowish-green pasty material
Case 1: we encountered two patients who presented with almost identical gross and micro‐
scopic findings at EUS-FNA. The first patient was a 52-year-old male with a past medical
history of acute gallstone pancreatitis 4 years prior, treated by cholecystectomy. He has had
no other episodes of pancreatitis after the surgery. During a workup for his nephrolithiasis,
CT scan incidentally identified a 3 cm unilocular cyst adjacent to the neck and body of his
pancreas. Endoscopic ultrasound was requested in order to evaluate this peri-pancreatic
cystic lesion. On site, EUS revealed a 3.4 cm primarily hypoechoic lesion. Aspirated material
had an unusual yellowish-green gross appearance with a pasty texture. Microscopically, the
smears contain rare squamous cells of gut luminal origin, abundant amorphous material
and acellular debris (Figure 1, A). A Hall’s stain for bilirubin showed focal staining, sugges‐
tive of bile pigment (Figure 1, B). Serum amylase assay was within normal range during this
period. In light of the cytological finding and clinical presentation, it was felt that the lesion
was most consistent with a small, chronic biloma, which likely developed at the time of his
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cholecystectomy. Follow up CT scan revealed an unchanged cyst and no further evaluation
was recommended.
Figure 1. Representative cytologic findings in a case of biloma. Panel A:High-power view showing abundant amor‐
phous material and acellular debris (Papanicolaou stain, 400x). Panel B: A Hall’s stain for bilirubin showed focal stain‐
ing, suggestive of bile pigment (Hall’s stain, 400x).
Case 2: the second patient was a 39-year-old male with a history of chronic pancreatitis.
During the workup for his intermittent upper abdominal pain, CT scan revealed a 2 cm hy‐
podense mass off the tail of his pancreas. The patient underwent EUS-FNA twice. Each time
EUS revealed a 2cm hypoechoic mass off the tail of the pancreas and grossly similar copious
yellowish-green material was aspirated and submitted for cytology. Microscopically, both
EUS-FNA specimens from this patient revealed almost identical findings as our previous
case with abundant bile-stained cyst contents and amorphous debris (Data not shown). No
inflammation was present. Concurrent serum CA19-9 assay was within normal limits. Al‐
though a specific diagnosis of biloma was not rendered on the original report, findings ar‐
gue for a benign cystic lesion and a CT follow-up for the stability of the lesion was
recommended without further intervention.
3.2. Pattern 2: Grossly tan-white cheesy material
Case 3: this was a 42-year-old male with chronic alcohol use and chronic hepatitis B and HIV
co-infection. CT scan found a cystic lesion near the pancreatic tail, which had been stable in
size. EUS identified a 2.5 cm complex cystic lesion adjacent to the pancreatic tail with both cyst‐
ic and solid components. Aspirated material was grossly tan-white in color and semi-solid,
cheesy in texture. Most of the material was lost during processing when air-dried or alcohol-
fixed slides with Diff-Quik or Papanicolaou staining was attempted. Microscopic examination
only revealed abundant amorphous degenerate material (Figure 2, A). Given the suspicion that
material was dissolved by alcohol, Oil-Red O stain was performed on air-dried slides and
showed variable fat staining (Figure 2, B). Because of the unusual gross appearance, the aspi‐
rated material on site was also sent for microbiology (negative findings) and assayed for CEA
(164971 ng/ml), and amylase (2357 u/L). The significantly elevated CEA level was concerning
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for malignancy. The patient subsequently underwent a distal pancreatectomy and splenecto‐
my. Surgical pathology specimen revealed a cyst present in the adipose tissue adjacent to the
pancreas filled with tan-white cheesy material. Microscopically, the cyst is lined by mature ker‐
atinizing squamous epithelium and lymphoid tissue with germinal centers surrounding the
epithelium, consistent with a lymphoepithelial cyst (LEC) of the pancreas (Figure 2, C & D).
The possibility of a dermoid cyst was also considered due to the evident sebaceous gland dif‐
ferentiation beneath the squamous epithelium. However, the lack of hair follicles and sweat
glands and the presence of dense lymphoid tissue with germinal centers were most consistent
with the diagnosis of LEC of the pancreas. We presume that the abundant oily material filling
the cyst was partially due to the secretion of the sebaceous glands that accumulated intracyto‐
plasmic lipid droplets and produced oily sebum extracellularly. Mixed in with keratin debris,
this material could account for the unusual gross-appearance of that tan-white semi-solid athe‐
romatous material aspirated from this patient on EUS-FNA.
Figure 2. Microscopic findings of a lymphoepithelial cyst of pancreas with sebaceous differentiation. Panel A:High-
power view of cytology aspiration revealing abundant amorphous degenerate material (Papanicolaou stain, 400x).
Panel B:Oil-Red O stain on air-dried slides showing focally variable fat staining (Oil-Red O 100x). Panel C:Low-power
view of the subsequent surgical pathology specimen revealing a pancreatic cystic lesion lined by mature keratinizing
squamous epithelium and lymphoid tissue with germinal centers surrounding the epithelium (Hematoxylin and eosin
stain, 100x). Panel D:High-power view showing evident sebaceous gland differentiation of the squamous epithelial
lining of the cyst (Hematoxylin and eosin stain, 400x).
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3.3. Pattern 3: Grossly amber clear fluid, can be darker due to thickness
Cases 4-6: a computer inventory search from year 1997-2007 at University of Washington al‐
lowed us to review three additional cases of lymphoepithelial cysts with cytological diagno‐
sis and follow-up surgical resections. The features of these 3 cases are summarized in Table
5. All those surgical-proven lymphoepithelial cysts showed grossly clear fluid on cytology
aspiration with color variation described from light yellow to darker-brown. Available labo‐
ratory data showed low amylase and CEA level. The follow-up surgical specimens revealed
simple lymphoepithelial cysts with no sebaceous gland differentiation.
Cases 7-8: also included in Table 5 are two cases of surgical-proven pancreatic pseudocyst
that presented with grossly similar amber clear to brownish fluid on aspiration while con‐
current amylase and CEA level were in the normal range.
Case 4 5 6 7 8
Patient 35 yo M 42 yo F 51 yo M 42 yo F 60 yo F
Surgical
Diagnosis
LEC LEC LEC Pseudocyst Pseudocyst
Clinical
History
Lower
quadrant colic
pain for 9
months.
Questionable mild
chronic pancreatitis
Choledocolithiasis, s/p
cholecystectomy and 3
weeks abdominal pain
Alcohol use; 10yr h/o
epigastric pain
Alcohol use; liver
cirrhosis and
chronic pancreatitis
Imaging
Study
4.6 cm cystic
lesion at the
junction of
pancreatic
head and body
3.4 cm well-
circumscribed
radiolucent mass
4. 5 cm heterogeneous
microcystic mass adjacent
to the uncinate process
3.5 cm circumscribed,
heterogenous
pancreatic head mass
3.3 cm well
demarcated,
heterogeneous
pancreatic head
mass
Gross on EUS-
FNA
Clear light
yellow fluid
Clear fluid No fluid obtained Serosanguinous fluid Brownish fluid
Cytology Dx Cystic contents
and debris, no
epithelium
identified
Rare degenerated
cells and
proteinaceous
debris
Degenerative and
necrotic adipose tissue
Inflammatory cells,
hemosiderin pigment
and debris
Inflammatory cells
and fragments of
fibrous tissue
Lab Data Amylase:
24-354 U/L;
CEA:25.6-34. 5
ng/ml
CA19-9:8 U/ml
Amylase:35 U/L;
CA19-9:12 U/ml
Amylase:13-53 U/L; Amylase:18-54 U/L;
CEA:3.1 ng/ml
CA19-9:4.5-6.1 U/ml
Amylase:12-15 U/L;
* Both lymphoepithelial cyst (LEC) and pancreatic pseudocyst can grossly show amber clear fluid upon fine needle aspi‐
ration. Fluid can also be thicker in texture and darker in color due to hemorrhagic changes.
Table 5. Salient features of 3 cases of LEC and 2 cases of pancreatic pseudocyst.
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Our experience tells us that being fully aware of the limitations on cytology diagnosis and
the  high possibility  of  non-representative  sampling of  the  lesions,  cytologists  should be
ready to reject or classify the specimens as non-diagnostic in many situations of acellular
cytological material and thus avoid misleading the clinical decisions with an erroneous di‐
agnosis. On the other hand, based on the individual institute settings and the availabilities
of cytopathologists for on-site immediate assessment,  cytology diagnosis tends to ignore
the gross appearance of the aspirated material and the background material is also often
overlooked  microscopically,  especially  in  an  acellular  cytology  specimen.  Incorporating
those  gross  material  observations  can  sometimes  add  valuable  information  towards  a
pathological diagnosis.
We presented three entities (8 cases) here in an attempt to highlight the diagnostic value of
gross appearance in fine needle aspiration cytology that can provide clues to the nature of
a pancreatic or a peripancreatic cystic lesion. These three entities: biloma, pancreatic lym‐
phoepithelial  cyst  and  pancreatic  pseudocyst,  although  considered  uncommon  and  not
widely  represented in  the  cytology literature,  are  actually  encountered more  commonly
now with the rapid advance of our imaging and imaging guided-sampling practices. On
cytology specimens, those are the lesions that generally produce acellular or sparsely cellu‐
lar material (not including carryover material from gastrointestinal luminal origin). How‐
ever by carefully combining the clinical,  radiological,  laboratory and cytological findings
grossly and microscopically, cytology can help lead to or confirm clinical judgments and
aid in patient care.
A biloma is an encapsulated bile collection outside the biliary tree. The underlying causes
include iatrogenic, traumatic, and spontaneous injury of the biliary tree causing bile leaks.
Its diagnosis can be established upon clinical history, imaging studies, and needle aspiration
cytology and chemical analysis of the aspirated fluid. The symptomatic biloma if left un‐
treated may result in significant morbidity and mortality. However, non-surgical interven‐
tion is considered the first choice of treatment for biloma, especially in many asymptomatic
situations. Alternatively symptomatic biloma may be treated successfully with intervention‐
al radiologic techniques instead of open surgery [54, 55]. It was recently reported that endo‐
scopic ultrasound-guided fine-needle aspiration of an infected biloma, together with
endoscopic biliary stent placement, resulted in complete resolution of a patient’s biloma
[56]. Thus, cytological diagnosis of biloma upon EUS-FNA can help a great deal in manag‐
ing this potentially complex problem.
A wide variety of cystic lesions can arise within or adjacent to the pancreas. They can be
generally placed into non-neoplastic and neoplastic categories. The non-neoplastic cystic le‐
sions can be both congenital and acquired. EUS-FNA has emerged as the primary choice for
obtaining diagnostic material on pancreatic cystic lesions. Aspirated cystic fluid analysis for
pancreatic enzymes, tumor markers, and fluid viscosity can be of great help in the differen‐
tial diagnosis. Non-neoplastic cysts generally are high on amylase level and low on tumor
markers (CEA, CA 19-9) while these tumor markers are generally elevated in malignant
cystic neoplasms, but low in non-neoplastic or benign neoplastic cysts. Having said that, ex‐
ceptions do occur and no standardized values exist among institutions. On cytology speci‐
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men, neoplastic cystic lesions usually produce a more cellular aspirate compared to non-
neoplastic cysts if appropriately sampled.
The acquired non-neoplastic pancreatic cysts include dermoid cysts, LECs and pseudocysts.
Both dermoid cysts and LECs are squamous-lined non-neoplastic cysts. LECs are benign
cystic lesions [57] seen predominantly in males, in the fifth to sixth decades of life. They may
be unilocular or multilocular. The cyst contents may vary from serous to cheesy/casseous-
appearing material depending on the degree of keratin formation. Microscopically, the cysts
are lined by well-differentiated stratified squamous epithelium, which may or may not have
prominent keratinization. In some areas, the lining may appear more transitional, and in
others, flat, cuboidal, or focally denuded. The squamous epithelium is surrounded by a
band of dense lymphoid tissue composed of mature T-lymphocytes with intervening germi‐
nal centers formed by B cells. The representative aspirate findings are non-specific, showing
a mixed population of lymphocytes, histiocytes in a background of keratin debris and pro‐
teinaceous debris. Squamous lining cells may be seen. The occurrence of sebaceous glands in
LEC of pancreas is well documented [58]. It is unclear whether the florid sebaceous glandu‐
lar differentiation correlates with the exceedingly elevated CEA and amylase level in our pa‐
tient. LECs of the pancreas do not appear to be associated with any autoimmune conditions,
human immunodeficiency virus infection, lymphoma, or carcinoma. All of these lesions
have been documented to occur in their salivary gland counterparts [59]. Dermoid cysts are
also rare in the pancreas region. They are reported in younger patients (2nd-3rd decades). The
presence of sebaceous glands or hair follicles and absence of closely associated lymphoid tis‐
sue is more typical for dermoid cysts and differentiate them from LECs.
Pancreatic pseudocysts account for the vast majority (75-90%) of pancreatic cysts [60]. Pseu‐
docyst lacks an epithelial lining. It develops when a focus of peri-pancreatic fat necrosis is
resorbed, producing a debris-filled space rich in pancreatic exocrine enzymes. It is in general
composed of an inflammatory fibrous capsule surrounding a region of necrosis. However,
the pathologic findings may vary depending on the stage of the process. The cyst contents,
originally necrotic fat, transform into a mixture of necrotic cells, enzymes, scavenger cells,
cholesterol clefts and sometimes neutrophils. The tissue that surrounds the necrotic material
first produces granulation tissue, and eventually becomes a fibrotic pseudocapsule. FNA
usually yields clear to dark brown fluid, which often but not always (as in our cases) shows
elevated amylase level on fluid analysis. Aspirate smears are again non-specific and com‐
posed of granular necrotic debris and mixed inflammatory cells [61]. A clinical history of
pancreatitis and confirmatory gross evidence of pancreatitis on imaging should confirm the
diagnosis. The diagnosis of pseudocyst on cytology should be considered one of exclusion.
4. Aim 3: Application of immunocytochemistry (ICC) studies in EUS-
FNA obtained cytology material
When applying ancillary techniques in cytologic specimens, cytopathologists often encoun‐
ter the difficulties of limited material, lack of negative or positive controls or lack of internal
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controls. On the other hand, the presence of internal control material can sometimes add
confusion rather than reassurance in ICC-stained material. Nevertheless, by carefully and
strategically using the cytology specimen, immunocytochemical studies are often achievable
with limited aspiration material. We have used some of the techniques that have been de‐
scribed by others, such as immunostaining over Papanicolaou-stained monolayer slides; ap‐
plying different antibodies to different areas of one smear slide; or making cell block
preparations whenever possible. When unstained material is not available and no cell block
is initially prepared, Dr. V. Grieco and her colleagues at Harborview Medical Center, Seattle,
Washington, have used a scraped slide technique that transfers smear material on Papanico‐
laou stained slides into paraffin embedded cell blocks. The cell block can then be used for
ICC with appropriate controls. If successful, this may avoid the necessity of obtaining addi‐
tional tissue. We have routinely used this scraped cell block technique in our daily practice
as well as in research projects. We hereby briefly discuss our mucin study project with ar‐
chival cytology material from 1997-2007 at University of Washington, presented at Digestive
Disease Week [62]. Schema of Scraping Technique is illustrated in Figure 3: scraping the ma‐
terial from rehydrated direct smear slides into a cell block preparation.
Figure 3. Schema of Scrapped Cell Block Technique:Papanicolaou-stained cellular direct smears are placed in xylene,
coverslip removed, and re-hydrated in sequentially graded ethanol to tap water. The cellular material is then scraped
from the glass slides using a razor blade, embedded in Histogel and processed with routine cell block preparation.
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Cytology diagnosis of mucin-producing pancreatic neoplasms including mucinous non-
cystic carcinoma (colloid carcinoma), mucinous cystic neoplasm, and intraductal papillary-
mucinous neoplasm (IPMN) is important because of the speculation that disruption of the
integrity of these mucinous tumors by an incisional biopsy may cause dissemination of tu‐
mor cells with mucin and worsen the prognosis. Mucin-detection is not always an easy task
on EUS-FNA specimen. Reactive/inflammatory pancreatitis can cause dilated ducts and‐
pseudocyst formation with proteinaceous precipitate that can be mistaken as mucinous ma‐
terial. Sheets of carry-over gastric foveolar cells can mimic cells from mucinous neoplasia
[ 63-67]. By applying conventional cytochemistry including PAS (periodic acid-Schiff reac‐
tion), PASD (PAS with diastase), alcian blue and mucicarmin, in conjunction withmucin
protein (MUC1, MUC2) immunostaining on surgical-proven cytology specimens, this study
aims at selecting a practical diagnostic tool to enhance the diagnostic accuracy of detecting
mucin-producing pancreatic neoplasms.
Studied material include: 1) Bench FNA specimens performed on autopsy or surgical-ob‐
tained normal tissue that are likely to be carried-over during an endoscopic procedure in‐
cluding pancreas, gastric body, pylorus and duodenum; 2) EUS-FNA (with scraped cell
block preparation by scraping archival smears into a cell block), along with subsequent sur‐
gical specimens on mucinous cystadenoma, borderline mucinous cystic neoplasm, IPMN,
colloid carcinoma and ductal adenocarcinma with mucin production; 3) Non-mucin produc‐
ing lesions including solid pseudopapillary tumor and chronic pancreatitis with dilated
duct. Our data demonstrate that mucicarmin is very insensitive in detecting mucin produc‐
tion. We are unable to show reliable mucicarmin staining on both surgical and cytology
specimen of IPMN(Figure 4, Panel D-F) as well as mucinous cystic neoplasia cases. MUC1
and MUC 2 immunostains do not consistently pick up mucin production by pancreatic neo‐
plasia on cytology specimens either. In contrast, PAS/PAS-Diastase are a reliable and sensi‐
tive marker to stain background mucin material and mucin-producing epithelial cells on
cytology, yet specific enough to distinguish proteinaceous precipitate in a pancreatitis case
(Figure 4, Panel A-C, precipitate in a dilated duct that was mistaken as possible mucinous
material on cytology). The results have directed our daily practice on the use of mucin stains
on cytologic diagnosis of pancreatic mucinous neoplasia.
Concomitant use of ICC can greatly enhance the diagnostic accuracy on cytology specimens,
especially when it comes to the diagnostic entities invariably requiring immunophenotypic
identification, such as in the diagnosis of pancreatic endocrine neoplasia (PENs) [68-72].
However, due to the initial unanticipated nature of the lesion, lack of cytopathologist on site
or difficulties of the procedure, sufficient aspirate/biopsy material for cellblock preparation
is not always available. By using the scraped cell block technique, a select panel of immuno‐
cytochemical studies can be achieved to aid in the diagnosis of PEN. Using the aforemen‐
tioned scraped cell block technique, figure 5 shows strong expression of the neuroendocrine
immuno-marker, chromogranin, by the neoplastic cells. Figure 6 shows neoplastic cells
stained positively with the neuroendocrine marker, synaptophysin by directly applying the
antibody onto a Papanicolaou-stained charged monolayer slide.
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Figure 4. In a case of IPMN, with negative staining for mucicarmine and MUC1, PASD highlighted the mucinous neo‐
plastic cells uniformly (panel D-F). Negative PASD staining in a pancreatitis case with precipitate in a dilated duct that
was mistaken as possible mucinous material on cytology initially (panel A-C).
The Use of Endoscopic Ultrasound-Guided Fine Needle Aspiration (EUS-FNA) in Cytopathology Diagnosis
http://dx.doi.org/10.5772/52549
301
Figure 5. Immunocytochemical stain on a scraped cellblock section displaying strong expression of neuroendocrine
marker, Chromogranin by the neoplastic cells (Scraped material for cell block preparation, 400x).
Figure 6. Neoplastic cells on a monolayer slide stained positively with neuroendocrine marker, synaptophysin anti‐
body (400x)
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Before leaving this section, it should also be stated that in cytology, as in surgical pathology,
the light microscopic appearance of the tumor is more important than a particular staining
result and that immunocytochemistry should be used for confirmation of the cytomorpho‐
logical diagnosis. Be aware of that the staining of cytology specimens is often focal and
sometimes difficult to interpret, because of various factors, including limited material, high
background staining, and the presence of three-dimensional clusters with non-specific stain‐
ing and edge artifact. A combined clinical, radiographic and pathologic approach should al‐
ways be emphasized in rendering each diagnosis.
5. Aim 4: EUS-FNA as a source of material for molecular studies
We are at the beginning of the era of clinical application of molecular probes to assess genet‐
ic alterations. Many assays have become clinically available in identifying genetic alterations
that serve as prognostic markers and therapeutic targets. EGFR expression in head and neck
cancers, non-small cell lung carcinomas, colon cancers, and recently in pancreatic cancers
[73-82]; microsatellite instability tests in colon cancer serve as prognostic marker, therapeu‐
tic predictive marker and screening test for Lynch syndrome [83-88] are among the most
studied areas. Immunodetection of molecular markers on cytology specimen, especially in
cancer staging for metastatic disease will be playing a major role as a guide for molecular-
targeted therapy. EGFR expression has now been routinely assessed on cell block cytology
specimens by many of the commercial or academic laboratories. A prominent example in
this regard is FNA diagnosis of thyroid nodules. Given that the cytology reports on thyroid
FNA diagnoses are often indeterminate or suspicious, the potential use of diagnostic molec‐
ular markers as adjunct methods for cytologic diagnosis appears to be among the most
promising area of research [89-98]. Fluorescent (FISH) and chromogenic (CISH) in situ hy‐
bridization have recently become part of the diagnostic armamentarium of breast patholo‐
gists. HER2 gene amplification testing by FISH and/or CISH has become an integral part of
the diagnostic workup for patients with breast cancer [99-105 ]. FISH or CISH is now used in
FNA material with success in many situations, including HER2 assessment in FNA with ex‐
cellent correlation with the histologic specimens [106-108 ]. Many other applications, such as
N-myc amplication on FNA from neuroblastomas [109, 110] and potential use of multiplex
FISH for detection of recurrence of transitional carcinomas on urine specimens [111-114] are
also well documented molecular tests using cytology specimens.
Compared to paraffin-embedded tissue, cytology specimens offer the advantage of disag‐
gregated, intact cells, with fewer problems associated with tumor cell homogenization. FISH
or CISH probe for diagnosis should be expected to be detected more accurately in cytologic
specimen as it contains whole cells and whole nuclei. For the patient, the advantages include
low cost, prompt access and the avoidance of surgery.
In carcinogenesis,  the majority of molecular alterations occur prior to progressive tumor
growth. It has been well documented that resection of small (early) pancreatic tumors and tu‐
mors of low histological or cytological grade and stage are correlated with improved survival.
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It is, therefore, important to identify these tumors in their early stages. DNA methylation
changes are an early event in carcinogenesis and are often present in the precursor lesions of
various cancers. Dr. N. Kiviat’s lab at Harborview Medical Center, Seattle, Washington, has
published extensively in constructing a panel of candidate hypermethylated genes with opti‐
mal sensitivity and specificity as a potential screening tool for cervical neoplasia, ovarian car‐
cinoma and lung cancer [115-118]. In collaboration with Dr. N. Kiviat’s lab, we performed
molecular tests on EUS-FNA of pancreatic lesions in the form of remains in liquid-based prep‐
aration, together with bench-performed mock FNA from normal pancreas obtained through
Harborview trauma center. We preliminarily tested the hypothesis that a panel of hyperme‐
thylated genes with high sensitivity and specificity for pancreatic adenocarcinoma might in‐
crease the accuracy of diagnosis of FNA and brush cytology on pancreatic cancer.
Method Excess material from five pancreatic FNAs, three pancreatic duct brushings and
nine bile duct brushings from patients who subsequently had histologic evaluation upon
surgery were studied. Genomic DNA was isolated from residual cytology brushing sample
pellets using QIAamp Blood DNA isolation kit and methylation status of seven genes, was
accessed using MethyLight assay after bisulfite conversion [115]. These genes were reported
to be frequently methylated in other cancers, including RASSF1A (Ras association domain
family 1A gene), UCHL1 (ubiquitin carboxyl-terminal esterase L1), APC (adenomatosis pol‐
yposis coli), IGSF4 (also called CADM1, cell adhesion molecule 1), CDH13 (cadherin 13),
CCND2 (cyclin D2), and CDKN2A (cyclin-dependent kinase inhibitor 2A, p16). Primers and
probes for these genes are listed in Table 6. Sample adequacy after bisulfite conversion was
determined by amplification of β-actin gene (ACTB). The percentage of methylated refer‐
ence (PMR) for each gene was calculated as before [115]. The methylation status of a sample
was categorized in two ways: as having any methylation present (PMR>0) and as having
high levels of methylation (PMR≥4%), as previously described [115].
Gene Forward primer (5'-3') Probe (5'-3') Reverse primer (5'-3')
ACTB TGGTGATGGAGGAGGTTTAGTAAGT
6FAM-
ACCACCACCCAACACACAATAACAAACACA-
TAMRA
AACCAATAAAACCTACTCCTCCCTTAA
APC TTATATGTCGGTTACGTGCGTTTATAT 6FAM-CCCGTCGAAAACCCGCCGATTA-TAMRA GAACCAAAACGCTCCCCAT
CCND2 CGTGTTAGGGTCGATCGTGTT 6FAM-ACTACGATAAAATCGCCG-MGB CTCGCCAAACTTTCTCCCTAAA
CDH13 GATTTTTGGGTTCGGAATGATTT 6FAM-TTTTCGTCGTCGCGATC-MGB ATCGCCCGACACGAACAA
CDKN2A TGGAGTTTTCGGTTGATTGGTT 6FAM-ACCCGACCCCGAACCGCG-TAMRA AACAACGCCCGCACCTCCT
IGSF4 AGGGAGCGAGGTTTTTCGA 6FAM-CGAACCCAACCCGAC-MGB ACGAAATCCGAACAAACCAATC
RASSF1 TAGGTTTTTATTGCGCGGTTTT 6FAM-CGCGAACCGAACGAA-MGB TACTTCGCTAACTTTAAACGCTAACAA
UCHL1 TCGCGAAGATGTAGTTTAAGTCGAT 6FAM-ACGCTCACCTCGAAAT-MGB CGCGCTCTCCGAATAACG
Table 6. Primers and probes for MethyLight assays
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Results A total of 17 samples were available for examination. No DNA remained in one bile
duct brushing after preparation of smears for microscopic examination. Thus, 16 samples, 12
malignant and 4 benign (by histology) were evaluated. On microscopic examination of the
FNA and brush cytologic specimens, 8 of the 12 samples which were later shown to be ma‐
lignant (on biopsy) were classified as “suspicious” for malignancy while four were called
definitively “positive” for malignancy by FNA or brush. The remaining four cases were his‐
tologically benign. Two of these cases were called “negative” on microscopic examination of
the FNA or brush specimen, one was classified as “atypical” and one as “suspicious for ma‐
lignancy”. The distribution of aberrantly methylated genes of interest among the benign and
malignant lesions is presented in Table 7.
Gene
Any Methylation
(PMR>0%)
High Methylation
(PMR≥4%)
Malignant
(n=12)
Benign
(n=4)
Malignant
(n=12)
Benign
(n=4)
UCHL1 9 (75%) 1 (25%) 6 (50%) 0 (0%)
APC 7 (58%) 1 (25%) 3 (25%) 0 (0%)
RASSF1 3 (25%) 0 (0%) 2 (17%) 0 (0%)
IGSF4 3 (25%) 0 (0%) 1 (8%) 0 (0%)
CDH13 8 (67%) 0 (0%) 3 (25%) 0 (0%)
CCND2 10 (83%) 4 (100%) 8 (67%) 2 (50%)
CDKN2A 0 (0%) 0 (0%) 0 (0%) 0 (0%)
CDH13 or RASSF1 (75%) 0%)
UCHL1, CDH13, or
RASSF1 (67%) (0%)
Table 7. Promoter Hypermethylation by Histologic Diagnosis
Methylation of  three different  genes (RASSF1,  IGSF4,  and CDH13) was present at  some
level in malignant but not benign samples, and methylation of two other genes (UCHL1
and APC) was present at a higher frequency in the majority of malignant samples but was
present in only one of four benign samples. For two genes, methylation was either present
in nearly all samples, regardless of histologic diagnosis (CCND2) or was not present in any
samples (CDKN2A). For five genes, high levels of methylation (PMR≥4%) were present in
malignant cases but were not detected in any of the benign samples. We next identified the
combination  of  genes  with  the  highest  sensitivity  and  specificity  for  pancreatic  cancer.
The Use of Endoscopic Ultrasound-Guided Fine Needle Aspiration (EUS-FNA) in Cytopathology Diagnosis
http://dx.doi.org/10.5772/52549
305
When any level of methylation was considered as positive, aberrant methylation of CDH13
or RASSF1 provided optimal sensitivity and specificity for cancer, being present in 75% of
malignant and 0% of benign specimens (Table 7). Considering high levels of methylation
(PMR≥4%), the most sensitive and specific combination of methylated genes was UCHL1,
CDH13 and RASSF1 which were positive in 67% of malignant but 0% of benign specimens
(Table 7). Next we examined, whether detection of aberrantly methylated genes might in‐
crease our ability to accurately classify FNA and brush specimens as “positive” or “nega‐
tive” for malignancy. Using this approach, FNA and brush specimens were classified as
“Positive for malignancy” if either cells with malignant morphologic changes or any level
of methylation of CDH13 or RASSF1 was present (Table 8). Specimens were called “Nega‐
tive for malignancy” if the cells were morphologically normal or cells were atypical or suspi‐
cious by morphology but there was no evidence of aberrant methylation of either CDH13 or
RASSF1. This algorithm detects 83% of malignant samples while maintaining 100% specif‐
icity. We are aware that an independent sample set is necessary to appropriately test this
algorithm; however, this pilot data suggests that a panel of hypermethylated tumor sup‐
pressor  genes  might  be  useful  in  distinguishing  malignancy  from benign  pancreatic  le‐
sions. A similarly sensitive and specific algorithm combining cytologic morphology and a
panel  of  genes methylated at  high levels  (PMR ≥4% of  UCHL1,  CDH13 and/or RASSF1
present) was also developed.
Final Diagnosis Malignant(n=12)
Benign
(n=4)
POSITIVE
morphology consistent with malignancy 4 (33%) 0 (0%)
or aberrant methylation of CDH13 9 (75%) 0 (0%)
or aberrant methylation of RASSF1 10 (83%) 0 (0%)
NEGATIVE
Negative morphology or 2 (50%)
Atypical or suspicious cell morphology but no aberrant methylation of CDH13 or RASSF1 4 (100%)
Table 8. Cytology or Any Methylation (PMR>0%) vs. Histology
Conclusions. Although the present study was limited by the fact that we were not able to
test these algorithms in an independent sample, it appears that FNA and brush cytologic
specimens can be more accurately classified as positive or negative for pancreatic cancer by
including methylation analysis of tumor suppressor genes.
The variable mixture of tumor cells and normal cells is a major challenge when it comes to
the molecular analysis of diagnostic or therapeutic targets in cytologic specimens. Cytolo‐
gists are needed to play an active role in the adoption and application of molecular techni‐
ques, since we are able to interpret the results in the light of cytological morphology. Our
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pilot data holds promise for further research to conduct a genome wide search for addition‐
al aberrantly methylated genes with high sensitivity and specificity for pancreatic cancer
and which are not methylated in other tissues (such as colon, liver, stomach, duodenum)
which can be frequently or incidentally present as carry-over material in FNA and brush
specimens from pancreatic lesions.
6. Aim 5: Achieving the full value of EUS-FNA with an integrated
approach: A EUS-FNA case study
A 67-year-old woman was found to have a large retroperitoneal mass of uncertain etiology.
The mass appears to invade the inferior vena cava and renal vein. Two prior attempts of CT
and ultrasound guided biopsy were non-diagnostic due to the biopsy specimen consisting
predominantly of necrotic tissue. Endoscopic ultrasound and enteroscopy were requested to
re-evaluate the lesion and re-attempt biopsy.
In the initial effort of EUS-FNA, rare clusters of neoplastic cells having round nuclear con‐
tour, mild nuclear crowding and overlapping, vesicular chromatin pattern, and distinct nu‐
cleoli are noted in a background of extensive necrosis and blood. Fresh material sent for
flow cytometry analysis contained an abnormal CD56- and EpCAM-positive population.
Abnormal B or T cell populations were not identified. A cytologic impression was issued as:
Positive for neoplasm with features suggestive of neuroendocrine origin. Before implement‐
ing chemotherapy as neuroendocrine tumor, our astute clinician ordered indiumIII octreo‐
tide scan for clinical correlation and found no evidence of focal radiotracer uptake in the
abdominal mass. The diagnosis was subsequently felt not sufficiently conclusive for therapy
as neuroendocrine neoplasia. A repeat biopsy was requested. During the second attempt of
EUS-FNA, there was extrinsic appearing compression at the second, third, and fourth por‐
tions of the duodenum with no evidence of mucosal lesions or ulcerations. A large (greater
than 12 cm) heterogeneous hypoechoic mass lesion was identified adjacent to the head and
neck of the pancreas. One component of the mass appeared to be cystic (Figure 7, panel A,
with needle inside the cystic area), and a more solid component was also identified (Figure
7, panel B). The former was sampled with FNA, the latter with a core biopsy. Nine total
FNA passes were obtained with on-site immediate interpretation:
Pass 1 (core biopsy):Blood and necrotic material, non-diagnostic.
Pass 2 (core biopsy):Blood, necrotic material and sheets of bland epithelium. Additional di‐
agnostic material requested.
Pass 3 (needle aspirate):Chiefly blood with atypical cells present.
Pass 4 (needle aspirate):Chiefly blood.
Pass 5 (needle aspirate):Chiefly blood.
Pass 6 (needle aspirate):Placed directly into saline.
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Pass 7 (needle aspirate):Atypical cells present, defer to permanents.
Pass 8 (needle aspirate):Atypical cells present, defer to permanents.
Pass 9 (needle aspirate):Placed directly into saline for cell block preparation.
Many clusters of viable cells were obtained during the second attempt of EUS-FNA, display‐
ing cytological features including three dimensional clusters, loose monolayer and individu‐
al monotonous cells, microfollicular pattern and nuclear grooves (coffee bean-like nuclei).
The tumor cells are uniform and lack nuclear hyperchromasia and pleomorphism (Figure 7,
panel C-E). Given the ample material obtained, a cell block was prepared and a more com‐
plete panel of antibodies for ICC was able to be performed, with the following results (19
antibody stains performed on cytology specimen, figure 7, panels E, F):
Antibody Results
AE1/AE3 Positive, focally
CALRETININ Positive
CD10 Negative
CD34 Negative
CD56 Positive, uniformly
CD68/KP-1 Negative
1A4 Positive, focally
DESMIN Negative
S100 Negative
CHROMOGRANIN Negative
SYNAPTOPHYSIN Negative
C-KIT Negative
INHIBIN Positive, uniformly
MELAN A Negative
CD45 (T200) Negative
EMA Negative
NSE Positive, focally
ER (clone 1D5) Negative
ER (clone SP1) Positive
Table 9.
Endoscopy308
Figure 7. EUS-FNA diagnosis of granulosa cell tumor. A heterogeneous hypoechoic mass lesion identified by EUS. One
component of the mass appearsto be cystic (panel A, with needle inside the cystic area); A more solid component
(panel B); Ample viable material obtained on repeat EUS-FNA (panel C, Pap smear 100 x); Cytomorphology of neoplas‐
tic cells on smear (panel D, oil immersion, 1000 x); Cytomorphology of neoplastic cells on cell block section (panel E, oil
immersion, 1000 x); Application of inhibin antibody on cell block section (panel F, 400 x).
The combined cytologic and immunophenotypic profile leads to the following final diagnosis:
Retroperitoneal mass, endoscopic ultrasound-guided FNA: Consistent with metastatic/
recurrent granulosa cell tumor. See comment.
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Comment: The cytologic appearance of this tumor, along with the overall immuno-pheno‐
type demonstrated by calretinin and inhibin positivity, supports the diagnosis of granulo‐
sa  cell  tumor.  Additional  studies  performed  at  PhenoPath  Laboratory  using  the  more
sensitive anti-ER antibody SP1 document expression of  estrogen receptor (in contrast  to
the  negative  anti-ER  studies  using  the  1D5  clone),  further  supporting  the  diagnosis  of
granulosa cell tumor.
After the diagnosis, patient recalls that she had a procedure for granulosa cell tumor about
30 years ago in Mexico.
Granulosa cell tumor may pose a diagnostic challenge in cytology preparations. First, there
is some similarity between the granulosa tumor cells and reactive mesothelial cells. Indis‐
tinct cell borders, high nuclear cytoplasmic ratio and indentation of the nuclear membrane
are helpful features in distinguishing granulosa tumor cells from mesothelial cells. Secondly,
although nuclear features, especially nuclear grooves, are one of the classic features on gran‐
ulosa cell tumor, they can also be seen in other ovarian tumors such as Brenner tumor and
other sex cord-stromal tumor. Other characteristic histological features for granulosa cell tu‐
mor, such as Call-Exner bodies, a second population of elongated theca cells, are rarely evi‐
dent on cytology specimens. Lastly, as occurred in our case, cells of carcinoid, especially
pancreatic neuroendocrine tumors in this anatomic site, share many features of granulosa
cells. Judicious use of a panel of immunocytochemistry (with the availability of sufficient
sampling material) can be of great help in this scenario. Granulosa cell tumor is positive for
inhibin, CD99, calretinin, vimentin, CD56, is generally negative for cytokeratin, EMA, Ber-
Ep4, and is negative for neuroendocrine markers synaptophysin and chromogranin. Brenner
tumor and other sex cord-stromal tumor usually are positive for cytokeratin and EMA.
As illustrated in this case, clinical-pathologic correlation is essential with octreotide scan
preventing a diagnostic pitfall of neuroendocrine neoplasia. The on-site cytology interpreta‐
tion performed for each of 9 EUS-FNA passes played a pivotal role in obtaining adequate
viable diagnostic material, considering the sampling difficulty due to extensive tumor ne‐
crosis despite the apparent large size of the tumor by imaging study. A more complete ICC
panel was thus able to be performed. The ICC results together with cytomorphology led to a
diagnosis consistent with the subsequently retrieved clinical history.
Thus, our final note: the full value of FNA is only achieved with the integrated approach:
the integration of clinical information, light microscopic analysis, results of ancillary studies,
and even the gross appearance of the aspiration material will inform and lead us to a more
accurate pathology diagnosis that can help tremendously in directing patient care.
Acknowledgements
The authors want to express their sincere gratitude to Drs. Nancy B. Kiviat (University of
Washington, Seattle, WA), Melissa P. Upton (University of Washington, Seattle, WA) and
Stephen J. Rulyak (Evergreen Medical Center, Gastroenterology, Seattle, WA), for their pro‐
fessional guidance, insightful discussions and tremendous technical support.
Endoscopy310
Author details
Lee-Ching Zhu1*, Qinghua Feng2 and Verena S. Grieco3
*Address all correspondence to: zhu.c@ghc.org
1 Anatomic Pathology, Group Health Permanente, Seattle, WA, USA
2 Department of Pathology, School of Medicine, University of Washington, Seattle, WA,
USA
3 Harborview Medical Center, Anatomic Pathology, Seattle, WA, USA
References
[1] Rosch T, Lightdale CJ, Botet JF, et al:Localization of pancreatic endocrine tumors by
endoscopic ultrasonography. N Engl J Med.1992;326(26):1721-26.
[2] Voss M, Hammel P, Molas G, et al:Value of endoscopic ultrasound guided fine nee‐
dle aspiration biopsy in the diagnosis of solid pancreatic masses. Gut.Feb 2000;46(2):
244-9.
[3] Yoshinaga S, Suzuki H, Oda I, Saito Y:Role of endoscopic ultrasound-guided fine
needle aspiration (EUS-FNA) for diagnosis of solid pancreatic masses.Dig Endosc;
2011 May;23Suppl 1:29-33.
[4] Zhang S, Defrias DV, Alasadi R, Nayar R:Endoscopic ultrasound-guided fine needle
aspiration (EUS-FNA): experience of an academic centre in the USA. Cytopathology;
2010 Feb;21(1):35-43.
[5] Hwang CY, Lee SS, Song TJ, Moon SH, Lee D, Park do H, Seo DW, Lee SK, Kim
MH:Endoscopic ultrasound guided fine needle aspiration biopsy in diagnosis of pan‐
creatic and peripancreatic lesions: a single center experience in Korea. Gut Liver;
2009 Jun;3(2):116-21.
[6] Raddaoui E:Clinical utility and diagnostic accuracy of endoscopic ultrasound-guided
fine needle aspiration of pancreatic lesions: Saudi Arabian experience.ActaCytol;
2011;55(1):26-9.
[7] Fisher L, Segarajasingam DS, Stewart C, Deboer WB, Yusoff IF:Endoscopic ultra‐
sound guided fine needle aspiration of solid pancreatic lesions: Performance and
outcomes.J GastroenterolHepatol; 2009 Jan;24(1):90-6.
[8] Nakahara O, Yamao K, Bhatia V, Sawaki A, Mizuno N, Takagi T, Shimizu Y, Koshi‐
kawa T, Yatabe Y, Baba H:Usefulness of endoscopic ultrasound-guided fine needle
The Use of Endoscopic Ultrasound-Guided Fine Needle Aspiration (EUS-FNA) in Cytopathology Diagnosis
http://dx.doi.org/10.5772/52549
311
aspiration (EUS-FNA) for undiagnosed intra-abdominal lymphadenopathy.J Gastro‐
enterol; 2009;44(6):562-7.
[9] Moehler M, Voigt J, Kastor M, Heil M, Sengespeick C, Biesterfeld S, Dippold W, Kan‐
zler S, Galle PR:Endoscopic ultrasonography-guided fine-needle aspiration (EUS-
FNA) as primary diagnostic tool for unclear lesions in the upper gastrointestinal
tract.Dtsch Med Wochenschr; 2011 Feb;136(7):303-8.
[10] Fritscher-Ravens A, Izbicki JR, Sriram PV, et al:Endosonography-guided, fine-needle
aspiration cytology extending the indication for organ-preserving pancreatic sur‐
gery.Am J Gastroenterol. Sep 2000;95(9):2255-2260.
[11] Erickson, RA: EUS-guided FNA.GastrointestEndosc. 2004 Aug;60(2):267-79.
[12] De Bellis M, Sherman S, et al:Tissue sampling at ERCP in suspected malignant biliary
strictures, part 1, GastrointestEndosc2002;56:552-61.
[13] De Bellis M, Sherman S, et al:Tissue sampling at ERCP in suspected malignant biliary
strictures, part 2, GastrointestEndosc2002;56:720-30.
[14] Vandervoort J, Soetikno RM, et al:Accuracy and complication rate of brush cytology
from bile duct versus pancreatic duct.GastrointestEndosc 1999;49:322-7.
[15] Rösch T, Lorenz R, Braig C et al: Endoscopic ultrasound in small pancreatic tumors.
Z Gastroenterol 1991;29:110-5.
[16] Vilmann P, Saftoiu A:Endoscopic ultrasound-guided fine needle aspiration biop‐
sy:equipment and technique.J GastroenterolHepatol.Nov2006;21(11):1646-1655.
[17] AabakkenL, Silvestri GA, Hawes R, et al:Cost-efficacy of endoscopic ultrasonogra‐
phy with fine-needle aspiration vs. mediastinotomy in patients with lung cancer and
suspected mediastinaladenopathy.Endoscopy 1999;31:707-11.
[18] Harewood GC, Wiersema MJ, Edell ES, et al: Cost-minimization analysis of alterna‐
tive diagnostic approaches in a modeled patient with non-small cell lung cancer and
subcarinal lymphadenopathy.Mayo ClinProc 2002;77:155-64.
[19] Harewood GC, Wiersema MJ:A cost analysis of endoscopic ultrasound in the evalua‐
tion of esophageal cancer.Am J Gastroenterol 2002;97:452-8.
[20] Harewood GC, Wiersema MJ:A cost analysis of endoscopic ultrasound in the evalua‐
tion of pancreatic head adenocarcinoma.Am J Gastroeneerol 2001;96:2651-6.
[21] Chen VK, Arguedas MR, Kilgore ML, et al:A cost-minimization of analysis of alterna‐
tive strategies in diagnosing pancreatic cancer.Am J Gastroenterol 2004;99:2223-34.
[22] O'Toole D, Palazzo L, Arotcarena R et al:Assessment of complications of EUS-guided
fine-needle aspiration.GastrointestEndosc 2001;53:470-4.
[23] Chieng DC, JhalaD, Jhala N et al:Endoscopic ultrasound –guided fine-needle aspira‐
tion biopsy: a study of 103 cases. Cancer 2002;96:232-9.
Endoscopy312
[24] Dumonceau JM, Polkowski M, Larghi A, Vilmann P, Giovannini M, Frossard JL,
Heresbach D, Pujol B, Fernández-EsparrachG, Vazquez-Sequeiros E, Ginès A:Euro‐
pean Society of Gastrointestinal Endoscopy.Indications, results, and clinical impact
of endoscopic ultrasound (EUS)-guided sampling in gastroenterology: European So‐
ciety of Gastrointestinal Endoscopy (ESGE) Clinical Guideline.Endoscopy; 2011 Oct;
43(10):897-912.
[25] Exocrine pancreas.In: Greene FL, Page DL, Fleming ID, et al. editors. AJCC cancer
staging handbook. 6thed. New York: Springer-Verlag;2002. p.182.
[26] Klapman JB, Chang KJ:Endoscopic ultrasound-guided fine-needle injection. Gastro‐
intestEndoscClin N Am. 2005 Jan;15(1):169-77.
[27] Tarantino I, Barresi, L:Interventional endoscopic ultrasound: Therapeutic capability
and potential.World GastrointestEndosc 2009 Oct 15;1(1):39-44.
[28] Cho CM, Dewitt J, Ai-Haddad M:Echo-endoscopy: new therapeutic frontiers. Miner‐
va GastroenterolDietol. 2011 Jun;57(2):139-58.
[29] Savides TJ, Donohue M, Hunt G, et al:EUS-guided FNA diagnostic yield of malig‐
nancy in solid pancreatic masses:a benchmark for quality performance measure‐
ment.GastrointestEndosc 2007;66:277-82.
[30] Layfield LJ, Bentz JS, and Gopez EV:Immediate on-site interpretation of fine-needle
aspiration smears: a cost and compensation analysis.Cancer 2001;93319-322.
[31] Schwartz MR: Endoscopic ultrasound-guided fine-needel aspiration-time, diagnostic
challenges and clnical impact. Cancer Cytopathology 2004;102(4):203-205.
[32] Klapman JB, Logrono R, Dye CE, et al:Clinical impact of on-site cytopathology inter‐
pretation on endoscopic ultrasound-guided fine needle aspiration.Am J Gastroenter‐
ol 2003;98:1289-94.
[33] Alsohaibani F, Girgis S, SandhaGS:Does onsite cytotechnology evaluation improve
the accuracy of endoscopic ultrasound-guided fine-needle aspiration biopsy?Can J
Gastroenterol. 2009 Jan;23(1):26-30.
[34] Jhala N, Jhala D,Etoum I, Vickers SM, et a:Endoscopic ultrasound-guided fine-needle
aspiration biopsy: a powerful tool to obtain samples from small lesions.Cancer
2004;102(4):239-246.
[35] Erickson RA, Sayage-Rable L, Beissner S:Factors predicting the number of EUS-guid‐
ed fine-needle passes for diagnosis of pancreatic malignancies. Gastrointestinal En‐
doscopy 2000;51(2):184-190.
[36] Jhala NC, Jhala DN, Chhieng DC, et a:Endoscopic ultrasound-guided fine-needle as‐
piration-a cytopathologist's perspective.AJCP 2003; 120(3):351-367.
The Use of Endoscopic Ultrasound-Guided Fine Needle Aspiration (EUS-FNA) in Cytopathology Diagnosis
http://dx.doi.org/10.5772/52549
313
[37] JhalaNC,Eltoum IA, Eloubeidi MA, et al:Providing on-site diagnosis of malignancy
on endoscopic-ultrasound-guided fine-needle aspiration: should it be done?Annals
DiagPathol 2007;11:176-181.
[38] Dumonceau JM, Koessler T, vanHooft JE, Fockens P:Endoscopic ultrasonography-
guided fine needle aspiration: Relatively low sensitivity in the endosonographer
population.World J Gastroenterol; 2012 May 21;18(19):2357-63.
[39] Iqbal S, Friedel D, Gupta M, Ogden L, Stavropoulos SN:Endoscopic-ultrasound-
guided fine-needle aspiration and the role of the cytopathologist in solid pancreatic
lesion diagnosis.Patholog Res Int; 2012;2012:317167.
[40] Cherian PT, Mohan P, Douiri A, Taniere P, Hejmadi RK, Mahon BS:Role of endo‐
scopic ultrasound-guided fine-needle aspiration in the diagnosis of solid pancreatic
and peripancreatic lesions: is onsite cytopathology necessary?HPB (Oxford); 2010
Aug;12(6):389-95.
[41] HikichiT, Irisawa A, Bhutani MS, et al:Endoscopic ultrasound-guided fine-needle as‐
piration of solid pancreatic masses with rapid on-site cytological evaluation by endo‐
sonographers without attendance of cytopathologists.J Gastroenterol2009;44(4):322-8.
[42] Nguyen YP, Maple, JT, Zhang, Q, et al:Reliability of gross visual assessment of speci‐
men adequacy during EUS-guided FNA of pancreatic masses.GastrointestEndosc
2009;69(7):1264-70.
[43] Boujaoude J:Role of endoscopic ultrasound in diagnosis and therapy of pancreatic
adenocarcinomas. World J Gastro 2007;13(27):3662-3666.
[44] Eltoum IA, Jhala CD, Crowe DR, et al:Cumulative sum procedure in evaluation of
EUS-guided FNA cytology: the learning curve and diagnostic performance beyond
sensitivity and specificity.Cytopathology 2007;18:143-50.
[45] Nasuti JF, Gupta PK and Baloch ZW:Diagnostic value and cost-effectiveness of on-
site evaluation of fine-needle aspiration specimens: review of 5,688 cases.Diagn. Cy‐
topathol. 2002;27:1-4.
[46] Shin HJC, Lahoti S, and Sneige N:Endoscopic ultrasound-guided fine-needle aspira‐
tion in 179 cases.Cancer (Cancer Cytopathol) 2002;96:174-80.
[47] Savoy AD, Raimondo M, Woodward TA, et al:Can endosonographers evaluate on-
site cytologic adequacy?A comparison with cytotechnologists.GastrointestEndosc
2007;65(7):953-7.
[48] de Jong K, Poley JW, van Hooft JE, Visser M, Bruno MJ, Fockens P:Endoscopic ultra‐
sound-guided fine-needle aspiration of pancreatic cystic lesions provides inadequate
material for cytology and laboratory analysis: initial results from a prospective
study.Endoscopy; 2011 Jul;43(7):585-90.
Endoscopy314
[49] Karim Z, Walker B, Lam E:Lymphoepithelial cysts of the pancreas: the use of endo‐
scopic ultrasound-guided fine-needle aspiration in diagnosis.Can J Gastroenterol;
2010 Jun;24(6):348-50.
[50] Barresi L, Tarantino I, Granata A, Curcio G, Traina M:Pancreatic cystic lesions: How
endoscopic ultrasound morphology and endoscopic ultrasound fine needle aspira‐
tion help unlock the diagnostic puzzle. World J GastrointestEndosc; 2012 Jun 16;4(6):
247-59.
[51] Bhatia V, Rastogi A, Saluja SS, Kumar M, Bihari C, Kalayarasan R, Gupta NL:Cystic
pancreatic lymphangioma. The first report of a preoperative pathological diagnosis
by endoscopic ultrasound-guided cyst aspiration. JOP; 2011 Sep;12(5):473-6.
[52] Coe AW, Evans J, Conway J:Pancreas cystic lymphangioma diagnosed with EUS-
FNA. JOP; 2012 May;13(3):282-4.
[53] ZhuLC and Grieco V:Diagnostic value of unusual gross appearance of aspirated ma‐
terial from endoscopic ultrasound-guided fine needle aspiration of pancreatic and
peripancreatic cystic lesions.ActaCytol. 2008 Sep-Oct;52(5):535-40.
[54] Dev V, Shah D, Gaw F, Lefor AT:Gastric outlet obstruction secondary to post chole‐
cystectomy biloma:case report and review of the literature. JSLS. 1998;2(2):185-8.
[55] Chang ML, Lin DY:Symptomless cyst formation at the location of a biloma resolved
with a single aspiration:case report. Chang Gung Med J. 2000;23(12):794-8.
[56] Ponnudurai, R:Endoscopic ultrasound-guided drainage of a biloma: A novel ap‐
proach. Endoscopy 2006;38:199.
[57] Policarpio-Nicolas,ML, Shami VM, Kahaleh M, Adams RB, Mallery S, Stanley MW,
Bardales RH, Stelow EB:Fine-needle aspiration cytology of pancreatic lymphoepithe‐
lial cysts. Cancer (Cancer Cytopathol) 2006;108:501-6.
[58] Fujiwara H, Kohno N, Nakaya S, Ishikawa Y:Lymphoepithelial cyst of the pancreas
with sebaceous differentiation. J Gastroenterol 2000;35:396-401.
[59] Adsay NV:Cystic lesions of the pancreas.Modern Pathology, 2007;20:S71-S93.
[60] Solcia EN, Capella C, Kloppel G:Tumors of the pancreas. Fascicle 20 in Atlas of Tu‐
mor Pathology, 3rd series. Armed Forces Institute of Pathology, Washington DC:1997,
215-223.
[61] Weinstein LJ: Pancreas, in Cytology, Diagnostic principles and clinical correlates. Ci‐
bas ES and Ducatman BS, Saunders, Philadelphia 2003, 367-382.
[62] Zhu L and GriecoV:Identifying mucin on cytology specimens from EUS-FNA proce‐
dures.Digestive Disease Week, Washington, DC, 2007.
[63] Ringel J, Löhr M:The MUC gene family: their role in diagnosis and early detection of
pancreatic cancer.Mol Cancer. 2003 Jan 7;2:9
The Use of Endoscopic Ultrasound-Guided Fine Needle Aspiration (EUS-FNA) in Cytopathology Diagnosis
http://dx.doi.org/10.5772/52549
315
[64] Hruban RH, Maitra A, Kern SE, Goggins M:Precursors to pancreatic cancer.Gastro‐
enterolClin North Am. 2007 Dec;36(4):831-49.
[65] Albores-Saavedra J, Simpson K, Dancer YJ, Hruban :.Intestinal type adenocarcinoma:
a previously unrecognized histologic variant of ductal carcinoma of the pan‐
creas.Ann DiagnPathol. 2007 Feb;11(1):3-9.
[66] Furukawa T, Klöppel G, VolkanAdsay N, et al:Classification of types of intraductal
papillary-mucinous neoplasm of the pancreas: a consensus study.Virchows Arch.
2005 Nov;447(5):794-9. Epub2005 Aug 9.
[67] Giorgadze TA, Peterman H, Baloch ZW, Furth EE, Pasha T, Shiina N, Zhang PJ, Gup‐
ta PK:Diagnostic utility of mucin profile in fine-needle aspiration specimens of the
pancreas: an immunohistochemical study with surgical pathology correlation.2006
Jun 25;108(3):186-97.
[68] Zhu L and Peck A: Endoscopic ultrasound guided fine needle aspiration of pancreat‐
ic endocrine neoplasms:Diagnostic challenges and the role of immunocytochemis‐
try.Check Sample, ASCP, 2008.
[69] Eloubeidi MA, Tamhane AR, Buxbaum J:Unusual, metastatic, or neuroendocrine tu‐
mor of the pancreas:a diagnosis with endoscopic ultrasound-guided fine-needle aspi‐
ration and immunohistochemistry.Saudi J Gastroenterol;2012 Mar-Apr;18(2):99-105.
[70] Chang F, Vu C, Chandra A, Meenan J, Herbert A:Endoscopic ultrasound-guided fine
needle aspiration cytology of pancreatic neuroendocrine tumours: cytomorphologi‐
cal and immunocytochemical evaluation. Cytopathology. Feb 2006;17(1):10-17.
[71] NotoharaK,Hamazaki S, Tsukayama C, et al:Solid-pseudopapillary tumor of the pan‐
creas: immunohistochemical localization of neuroendocrine markers and CD10. Am J
SurgPathol. Oct 2000;24(10):1361-1371.
[72] Portela-Gomes GM, Hacker GW, Weitgasser R:Neuroendocrine cell markers for pan‐
creatic islets and tumors.ApplImmunohistochemMolMorphol. 2004 Sep;12(3):183-92.
[73] Carlsson J:Potential for clinical radionuclide-based imaging and therapy of common
cancers expressing EGFR-family receptors.Tumour Biol. 2012 Jun;33(3):653-9. Epub
2012 Jan 7.
[74] Matthaios D, Zarogoulidis P, Balgouranidou I, Chatzaki E, Kakolyris S:Molecular
pathogenesis of pancreatic cancer and clinical perspectives.Oncology. 2011;81(3-4):
259-72. Epub 2011 Nov 23.
[75] Stella GM, Luisetti M, Inghilleri S, CemmiF,Scabini R, Zorzetto M, Pozzi E:Targeting
EGFR in non-small-cell lung cancer: lessons, experiences, strategies.Respir Med. 2012
Feb;106(2):173-83. Epub 2011 Nov 21
[76] Bohanes P, LaBonte MJ, Winder T, Lenz HJ:Predictive molecular classifiers in color‐
ectal cancer.SeminOncol. 2011 Aug;38(4):576-87.
Endoscopy316
[77] Cervera P, Fléjou JF:Changing pathology with changing drugs: tumors of the gastro‐
intestinal tract.Pathobiology.2011;78(2):76-89. doi: 10.1159/000315535. Epub 2011 Jun
15.
[78] Saijo N:Critical comments for roles of biomarkers in the diagnosis and treatment of
cancer.Cancer Treat Rev. 2012 Feb;38(1):63-7. Epub 2011 Jun 8.
[79] William WN Jr:Oral premalignant lesions: any progress with systemic therapies?Cur‐
rOpinOncol. 2012 May;24(3):205-10.
[80] Smith RA, Tang J, Tudur-Smith C, Neoptolemos JP, Ghaneh P:Meta-analysis of im‐
munohistochemical prognostic markers in resected pancreatic cancer.Br J Cancer.
2011 Apr 26;104(9):1440-51. Epub 2011 Mar 29. Review.
[81] Larsen AK, Ouaret D, El Ouadrani K, Petitprez A:Targeting EGFR and VEGF(R)
pathway cross-talk in tumor survival and angiogenesis.PharmacolTher. 2011 Jul;
131(1):80-90. Epub 2011 Mar 23.
[82] Murphy M, Stordal B:Erlotinib or gefitinib for the treatment of relapsed platinum
pretreated non-small cell lung cancer and ovarian cancer: a systematic review.Drug
Resist Updat. 2011 Jun;14(3):177-90. Epub 2011 Mar 24.
[83] Iacopetta B, Grieu F, Amanuel B:Microsatellite instability in colorectalcancer.Asia Pac
J ClinOncol. 2010 Dec;6(4):260-9. doi: 10.1111/j.1743-7563.2010.01335.x. Epub 2010 Oct
26.
[84] Imai K, Yamamoto H:Carcinogenesis and microsatellite instability: the interrelation‐
ship between genetics and epigenetics.Carcinogenesis. 2008 Apr;29(4):673-80. Epub
2007 Oct 17.
[85] Lawes DA, SenGupta S, BoulosPB:The clinical importance and prognostic implica‐
tions of microsatellite instability in sporadic cancer.Eur J SurgOncol. 2003 Apr;29(3):
201-12.
[86] Chapusot C, Martin L, Puig PL, Ponnelle T, Cheynel N, Bouvier AM, Rageot D,
Roignot P, Rat P, Faivre J, Piard F:What is the best way to assess microsatellite insta‐
bility status in colorectal cancer? Study on a population base of 462 colorectalcanc‐
ers.Am J SurgPathol. 2004 Dec;28(12):1553-9.
[87] Shia J, Ellis NA, Paty PB, Nash GM, Qin J, Offit K, Zhang XM, Markowitz AJ, Nafa K,
Guillem JG, Wong WD, Gerald WL, KlimstraDS:Value of histopathology in predict‐
ing microsatellite instability in hereditarynonpolyposiscolorectal cancer and sporadic
colorectalcancer.Am J SurgPathol. 2003 Nov;27(11):1407-17.
[88] Edmonston TB, Cuesta KH, Burkholder S, Barusevicius A, Rose D, Kovatich AJ, Bo‐
man B, Fry R, Fishel R, Palazzo JP:Colorectal carcinomas with high microsatellite in‐
stability: defining a distinct immunologic and molecular entity with respect to
prognosticmarkers.Hum Pathol. 2000 Dec;31(12):1506-14.
The Use of Endoscopic Ultrasound-Guided Fine Needle Aspiration (EUS-FNA) in Cytopathology Diagnosis
http://dx.doi.org/10.5772/52549
317
[89] Kouniavsky G, Zeiger MA:The quest for diagnostic molecular markers for thyroid
nodules with indeterminate or suspicious cytology.J SurgOncol. 2012 Apr 1;105(5):
438-43.
[90] Bartolazzi A, Bellotti C, Sciacchitano S:Methodology and technical requirements of
the galectin-3 test for the preoperative characterization of thyroidnodules.ApplIm‐
munohistochemMolMorphol. 2012 Jan;20(1):2-7. Review.
[91] Freitas BC, Cerutti J:.Genetic markers differentiating follicular thyroid carcinoma
from benign lesions.Mol Cell Endocrinol. 2010 May 28;321(1):77-85. Epub 2009 Nov
20.
[92] Nikiforova MN, NikiforovYE:Molecular diagnostics and predictors in thyroid can‐
cer.Thyroid. 2009 Dec;19(12):1351-61.
[93] Arora N, Scognamiglio T, Zhu B, Fahey TJ 3rd:Do benign thyroid nodules have malig‐
nant potential? An evidence-based review.World J Surg. 2008 Jul;32(7):1237-46.
[94] Carpi A, Nicolini A, Marchetti C, Iervasi G, Antonelli A, Carpi F:Percutaneous large-
needle aspiration biopsy histology of palpable thyroid nodules: technical and diag‐
nostic performance.Histopathology. 2007 Aug;51(2):249-57.
[95] Kapur U, WojcikEM:Follicular neoplasm of the thyroid--vanishing cytologicdiagno‐
sis?DiagnCytopathol. 2007 Aug;35(8):525-8.
[96] Ogilvie JB, Piatigorsky EJ, Clark OH:Current status of fine needle aspiration for thy‐
roidnodules.Adv Surg. 2006;40:223-38.
[97] Carpi A, Mechanick JI, Nicolini A, Rubello D, Iervasi G, Bonazzi V, Giardino :Thy‐
roid nodule evaluation: what have we really learned from recent clinical guidelines?
BiomedPharmacother. 2006 Sep;60(8):393-5. Epub 2006 Aug 4.
[98] Mechanick JI, Carpi A:Progress in the preoperative diagnosis of thyroid nodules:
managing uncertainties and the ultimate role for molecularinvestigation.Biomed‐
Pharmacother. 2006 Sep;60(8):396-404. Epub 2006 Aug 1
[99] Lambros MB, Natrajan R, Reis-FilhoJS:Chromogenic and fluorescent in situ hybridi‐
zation in breast cancer.HumPathol. 2007 Aug;38(8):1105-22.
[100] Lee JA, Shaheen M, Walke T, Daly M:Clinical and health economic outcomes of alter‐
native HER2 test strategies for guiding adjuvant trastuzumabtherapy.Expert Rev
Pharmacoecon Outcomes Res. 2011 Jun;11(3):325-41.
[101] Ross JS:Update on HER2 testing for breast and upper gastrointestinal tract can‐
cers.Biomark Med. 2011 Jun;5(3):307-18.
[102] Penault-Llorca F, Bilous M, Dowsett M, Hanna W, OsamuraRY, Rüschoff J, van de
Vijver M:Emerging technologies for assessing HER2amplification.Am J ClinPathol.
2009 Oct;132(4):539-48.
Endoscopy318
[103] Ross JS:Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2thera‐
py.Drug News Perspect. 2009 Mar;22(2):93-106.
[104] Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF:Guidelines for human epidermal
growth factor receptor 2 testing: biologic and methodologicconsiderations.JClinOn‐
col. 2009 Mar 10;27(8):1323-33. Epub 2009 Feb 9.
[105] Cuadros M, Villegas R:Systematicreview of HER2breast cancer testing.ApplImmuno‐
histochemMolMorphol. 2009 Jan;17(1):1-7.
[106] Bayani J, Squire JA:Fluorescence in situ Hybridization (FISH).CurrProtocCell Biol.
2004 Sep;Chapter 22:Unit 22.4.
[107] Shabaik A, Lin G, Peterson M, HastehF, Tipps A, Datnow B, Weidner N:Reliability of
Her2/neu, estrogen receptor, and progesterone receptor testing by immunohisto‐
chemistry on cell block of FNA and serous effusions from patients with primary and
metastatic breast carcinoma.DiagnCytopathol. 2011 May;39(5):328-32.
[108] Hanley KZ, Birdsong GG, Cohen C, SiddiquiMT:Immunohistochemical detection of
estrogen receptor, progesterone receptor, and human epidermal growth factor recep‐
tor 2 expression in breast carcinomas: comparison on cell block, needle-core, and tis‐
sue block preparations.Cancer. 2009 Aug 25;117(4):279-88.
[109] Barroca H, Carvalho JL, da Costa MJ,Cirnes L, Seruca R, Schmitt FC:Detection of N-
myc amplification in neuroblastomas using Southern blotting on fine needle aspi‐
rates.ActaCytol. 2001 Mar-Apr;45(2):169-72.
[110] Fröstad B, Martinsson T, Tani E, Falkmer U, Darnfors C, Skoog L, Kogner P:The use
of fine-needle aspiration cytology in the molecular characterization of neuroblastoma
in children.Cancer. 1999 Apr 25;87(2):60-8.
[111] Constantinou M, Binka-Kowalska A, Borkowska E, Zajac E, Jałmuzna P, Matych J,
Nawrocka A, Kałuzewski B:Application of multiplexFISH, CGH and MSSCP techni‐
ques for cytogenetic and molecular analysis of transitional cell carcinoma (TCC) cells
in voided urine specimens.J Appl Genet. 2006;47(3):273-5.
[112] Halling KC, KippBR:Bladder cancer detection using FISH (UroVysion assay).Ad‐
vAnatPathol. 2008 Sep;15(5):279-86.
[113] vanRhijn BW, van der Poel HG, van der KwastTH:Urine markers for bladder cancer
surveillance: a systematic review.Eur Urol. 2005 Jun;47(6):736-48. Epub 2005 Mar 23.
[114] Dey P:Urinary markers of bladder carcinoma.ClinChimActa. 2004 Feb;340(1-2):57-65.
[115] Feng Q, Balasubramanian, A, Hawes SE et al:Detection of hypermethylated genes in
women with and without cervical neoplasia.J Natl Cancer Inst 2005;97:273-82.
[116] Hawes SE, Stern JE, Feng Q, Wiens LW, Rasey JS, Lu H, Kiviat NB, Vesselle H:DNA‐
hypermethylation of tumors from non-small cell lung cancer (NSCLC) patients is as‐
The Use of Endoscopic Ultrasound-Guided Fine Needle Aspiration (EUS-FNA) in Cytopathology Diagnosis
http://dx.doi.org/10.5772/52549
319
sociated with gender and histologic type.Lung Cancer. 2010 Aug;69(2):172-9. Epub
2009 Nov 28.
[117] Feng Q, Deftereos G, Hawes SE, Stern JE, Willner JB, Swisher EM, Xi L, Drescher C, Ur‐
ban N, Kiviat NB:DNA hypermethylation, Her-2/neu overexpression and p53 muta‐
tions in ovarian carcinoma.GynecolOncol. 2008 Nov;111(2):320-9. Epub 2008 Aug 30.
[118] Feng Q, Hawes SE, Stern JE, Dem A, Sow PS, Dembele B, Toure P, Sova P, Laird PW, Kivi‐
at NB:Promoter hypermethylation of tumor suppressor genes in urine from patients
with cervical neoplasia.CancerEpidemiol Biomarkers Prev. 2007 Jun;16(6):1178-84.
Endoscopy320
